Shanghai Henlius Biotech (HKSE:02696) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02696 Shanghai Henlius Biotech Inc HKSE:02696
67 GF Score
Price HK$67.30
GF Value HK$30.91
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Shanghai Henlius Biotech Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Shanghai Henlius Biotech Valuation Rank Related Terms

HKSE:02696
67GF Score
Shanghai Henlius Biotech Inc HKSE:02696
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Shanghai Henlius Biotech (HKSE:02696) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Henlius Biotech stock appears to be overvalued. The current stock price of HK$67.30 is trading 117.7% above its estimated GF Value™ of HK$30.91. GuruFocus considers Shanghai Henlius Biotech to be Significantly Overvalued.

Key valuation signals for HKSE:02696:

  • Valuation Rank:
  • GF Value™: HK$30.91 vs. price of HK$67.30 (117.7% above fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the HKSE:02696 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Henlius Biotech Business Description

Other Exchanges 2E8:Germany
Address B8 Building, No. 188 Yizhou Road, 11th Floor, Xuhui District, Shanghai, CHN, 200233
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China, Asia Pacific (excluding Mainland China), North America, South America, Oceania, and Europe. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
67GF Score

Get the complete analysis for HKSE:02696

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$67.30
Price
HK$30.91
GF Value